A biotech and a micro-cap ridesharing rental provider entered the public market this past week, and seven companies submitted initial filings. After delaying its offering in the previous week, 89bio (ETNB) priced its upsized $85 million...read more
89bio, a Phase 1 biotech developing therapies for NASH and other metabolic diseases, raised $85 million by offering 5.3 million shares at $16, within the range of $15 to $17, to command a market value of $225 million. The company originally planned to raise $70...read more
After a busy week in the IPO market, just one biotech is scheduled to go public in the week ahead.
NASH biotech 89bio (ETNB) plans to raise $85 million at a $225 million market cap. The company’s target indication represents a multi...read more
Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more
US IPO Weekly Recap: NASH biotech jumps 69% as multi-billion dollar companies join the pipeline
A biotech and a micro-cap ridesharing rental provider entered the public market this past week, and seven companies submitted initial filings. After delaying its offering in the previous week, 89bio (ETNB) priced its upsized $85 million...read more
NASH biotech 89bio prices upsized IPO at $16 midpoint
89bio, a Phase 1 biotech developing therapies for NASH and other metabolic diseases, raised $85 million by offering 5.3 million shares at $16, within the range of $15 to $17, to command a market value of $225 million. The company originally planned to raise $70...read more
US IPO Week Ahead: Just 1 biotech is on the calendar in a slow week for the IPO market
After a busy week in the IPO market, just one biotech is scheduled to go public in the week ahead. NASH biotech 89bio (ETNB) plans to raise $85 million at a $225 million market cap. The company’s target indication represents a multi...read more
NASHville: 89bio is the latest biotech IPO targeting liver disease NASH
Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more